February 11, 2016
ARLINGTON, Va. — The Ensuring Patient Access and Effective Drug Enforcement Act of 2015 (S. 483), sponsored by Senators Orrin Hatch (R-Utah) and Sheldon Whitehouse (D-R.I.) was approved today following a markup by the Senate Judiciary Committee. The bill is the companion to H.R. 471, sponsored by Reps. Tom Marino (R-Pa.), Marsha Blackburn (R-Tenn.), Peter Welch (D-Vt.) and Judy Chu (D-Calif.), which was passed by the House of Representatives in April 2015.
Commenting on the legislation, HDMA President and CEO John M. Gray noted, “We are pleased that this bipartisan legislation – widely supported the pharmaceutical supply chain and dozens of patient and provider groups – has cleared an important hurdle on its way to what we hope will be full Senate passage. The Senate Judiciary Committee has clearly recognized that it takes the collaborative efforts of each segment of the pharmaceutical supply chain, as well as enforcement agencies, to effectively mitigate the scourge of prescription drug abuse in this country. We are hopeful that the full Senate will vote on this important legislation.”
HDA is the national association representing primary healthcare distributors, the vital link between the nation’s pharmaceutical manufacturers and healthcare providers. Each business day, HDA member companies ensure that over 15 million prescription medicines and healthcare products are delivered safely and efficiently to more than 200,000 pharmacies, hospitals, long-term care facilities, clinics and others nationwide. HDA and its members work daily to provide value and achieve cost savings, an estimated $42 billion each year to our nation’s healthcare system.